You are here

Article Text

Article menu

Download PDFPDF

Cervical cancer
2022-RA-421-ESGO DeflaGyn® has cytotoxic, genotoxic and apoptotic effects on human adenocancer cells: an in vitro study
Free
  1. Ayse Filiz Gokmen Karasu1,
  2. Gurkan Kiran2,
  3. Abdurrahim Kocyigit3,
  4. Norda Uckardes Katarmiyan4 and
  5. Eray Metin Guler5
  1. 1Minimal Invasive Surgery, Bezmialem Vakif University, Istanbul, Turkey
  2. 2Gynecologic Oncology, Bezmialem Vakif Universitty, Istanbul, Turkey
  3. 3Clinical Biochemistry, Bezmialem Vakif University, Istanbul, Turkey
  4. 4Obstetrics and Gynecology, Bezmialem Vakif University, Istanbul, Turkey
  5. 5Clinical Biochemistry, University of Health Sciences Hamidiye Medicine Faculty, Istanbul, Turkey

Abstract

Introduction/Background Recently an aqueous vaginal gel containing sodium 2- selenite pentahydrate and silicon dioxide (SiO2), has been marketed under the brand name DeflaGyn® for the eradication of HPV. Studies showing that Deflagyn®, which has been recommended to be used in various cytological abnormalities in recent years, regresses the severity of the lesions and causes the tests to turn negative in some of the HPV positive patients. The aim of the study was to determine whether DeflaGyn® has apoptotic, cytotoxic, and genotoxic properties on human cervical cancer cell (HeLa) lines.

Methodology Experiments were conducted on human cervical adenocarcinoma cell (HeLa) culture .The cells were incubated with different concentrations of DeflaGyn® for each experiment. Cell viability assay was performed based on luminometric ATP cell viability assay. Intracellular reactive oxygen species (ROS) was detected using 2,7-dichlorodihydrofluorescein-diacetate (H2DCF-DA) fluorescent probes. Genotoxicity was evaluated by alkaline single cell gel electrophoresis assay (Comet Assay). Apoptosis was evaluated by acridine orange/ethidium bromide (AO/EB) double staining method. 3,3’-dihexyloxacarbocyanine iodide (DiOC6(3)) was used to determine mitochondrial membrane potential (MMP).

Results Treatment with different doses of DeflaGyn® resulted in a higher cytotoxic effect in HeLa cells. DeflaGyn® increased the intracellular ROS production in a dose-dependent manner in HeLa cells. Dose-dependently increasing DeflaGyn® concentrations increased DNA damage. We have found that the MMP of HeLa cells decreased with increasing concentrations of DeflaGyn®.

Abstract 2022-RA-421-ESGO Figure 1
Abstract 2022-RA-421-ESGO Figure 1
Abstract 2022-RA-421-ESGO Figure 2
Abstract 2022-RA-421-ESGO Figure 2

Conclusion These findings indicate that cytotoxic, genotoxic and apoptotic effects at higher doses of DeflaGyn® may be due to its ROS production capacity. Our results only should be interpreted with caution as we are not suggesting that DeflaGyn® can be utilized in cancer treatment. Before clinical trials on humans, an in vivo experiment such as a tumor-bearing mice model may be studied.These cumulative, cytotoxic,genotoxic, apoptotic effects of Deflagyn may explain the mechanism on precancerous lesions.

https://doi.org/10.1136/ijgc-2022-ESGO.20

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.